Puma Biotechnology, Inc. PBYI
We take great care to ensure that the data presented and summarized in this overview for PUMA BIOTECHNOLOGY, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PBYI
View all-
Vanguard Group Inc Valley Forge, PA3.64MShares$9.85 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$9.68 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$8.3 Million0.42% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.88MShares$7.81 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.34 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.77MShares$4.8 Million0.01% of portfolio
-
Eversept Partners, LP New York, NY1.29MShares$3.5 Million0.26% of portfolio
-
Athyrium Capital Management, LP New York, NY1.26MShares$3.4 Million100.0% of portfolio
-
Geode Capital Management, LLC Boston, MA917KShares$2.49 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO875KShares$2.37 Million0.0% of portfolio
Latest Institutional Activity in PBYI
Top Purchases
Top Sells
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Insider Transactions at PBYI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2024
|
Michael Patrick Miller Director |
SELL
Open market or private sale
|
Direct |
23,358
-33.2%
|
$70,074
$3.49 P/Share
|
|
Jul 17
2024
|
Maximo F Nougues Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,156
-2.49%
|
$12,468
$3.7 P/Share
|
|
Jul 17
2024
|
Jeffrey Jerome Ludwig Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,598
-2.15%
|
$7,794
$3.7 P/Share
|
|
Jul 17
2024
|
Douglas M Hunt Officer |
SELL
Open market or private sale
|
Direct |
3,637
-2.66%
|
$10,911
$3.7 P/Share
|
|
Jul 17
2024
|
Alan H Auerbach President and CEO |
SELL
Open market or private sale
|
Direct |
21,920
-0.31%
|
$65,760
$3.7 P/Share
|
|
Jul 02
2024
|
Maximo F Nougues Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,295
-3.08%
|
$15,885
$3.27 P/Share
|
|
Jul 02
2024
|
Douglas M Hunt Officer |
SELL
Open market or private sale
|
Direct |
4,349
-3.08%
|
$13,047
$3.27 P/Share
|
|
Jul 02
2024
|
Jeffrey Jerome Ludwig Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,051
-4.76%
|
$18,153
$3.27 P/Share
|
|
Jul 02
2024
|
Alan H Auerbach President and CEO |
SELL
Open market or private sale
|
Direct |
18,885
-0.27%
|
$56,655
$3.27 P/Share
|
|
Jun 18
2024
|
Brian M Stuglik Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+26.2%
|
-
|
|
Jun 18
2024
|
Troy Edward Wilson Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+49.68%
|
-
|
|
Jun 18
2024
|
Michael Patrick Miller Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+22.07%
|
-
|
|
Jun 18
2024
|
Adrian Senderowicz Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+50.0%
|
-
|
|
Jun 18
2024
|
Alessandra Cesano Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+33.33%
|
-
|
|
Jun 18
2024
|
Allison Dorval Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+31.03%
|
-
|
|
Jun 18
2024
|
Jay M Moyes Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+35.85%
|
-
|
|
Jun 13
2024
|
Brian M Stuglik Director |
SELL
Open market or private sale
|
Direct |
9,900
-16.79%
|
$29,700
$3.39 P/Share
|
|
Jun 13
2024
|
Troy Edward Wilson Director |
SELL
Open market or private sale
|
Direct |
27,000
-98.72%
|
$81,000
$3.33 P/Share
|
|
Jun 13
2024
|
Jay M Moyes Director |
SELL
Open market or private sale
|
Direct |
22,000
-50.78%
|
$66,000
$3.34 P/Share
|
|
Jun 13
2024
|
Adrian Senderowicz Director |
SELL
Open market or private sale
|
Direct |
27,000
-100.0%
|
$81,000
$3.33 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 508K shares |
|---|
| Open market or private sale | 274K shares |
|---|